Aerie Pharmaceuticals Inc. [NASDAQ: AERI] loss -1.29% on the last trading session, reaching $15.30 price per share at the time. Aerie Pharmaceuticals Inc. represents 45.79 million in outstanding shares, while the company has a total market value of $694.93 million with the latest information. AERI stock price has been found in the range of $15.00 to $15.55.
If compared to the average trading volume of 1.02M shares, AERI reached a trading volume of 2455444 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
Here is what top equities market gurus are saying about Aerie Pharmaceuticals Inc. [AERI]:
Oppenheimer have made an estimate for Aerie Pharmaceuticals Inc. shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on June 01, 2020. While these analysts kept the previous recommendation, H.C. Wainwright dropped their target price from $37 to $31. The new note on the price target was released on May 07, 2020, representing the official price target for Aerie Pharmaceuticals Inc. stock. Previously, the target price had yet another raise to $27, while BofA/Merrill analysts kept a Neutral rating on AERI stock.
The Average True Range (ATR) for Aerie Pharmaceuticals Inc. is set at 0.98, with the Price to Sales ratio for AERI stock in the period of the last 12 months amounting to 8.75. The Price to Book ratio for the last quarter was 5.50, with the Price to Cash per share for the same quarter was set at 5.83.
Trading performance analysis for AERI stock
Aerie Pharmaceuticals Inc. [AERI] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 1.06. With this latest performance, AERI shares gained by 0.20% in over the last four-week period, additionally sinking by -22.98% over the last 6 months – not to mention a drop of -55.29% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for AERI stock in for the last two-week period is set at 51.41, with the RSI for the last a single of trading hit 53.59, and the three-weeks RSI is set at 51.14 for Aerie Pharmaceuticals Inc. [AERI]. The present Moving Average for the last 50 days of trading for this stock 14.70, while it was recorded at 15.15 for the last single week of trading, and 18.87 for the last 200 days.
Aerie Pharmaceuticals Inc. [AERI]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Aerie Pharmaceuticals Inc. [AERI] shares currently have an operating margin of -268.27 and a Gross Margin at +89.41. Aerie Pharmaceuticals Inc.’s Net Margin is presently recorded at -285.57.
Return on Total Capital for AERI is now -62.37, given the latest momentum, and Return on Invested Capital for the company is -67.03. Return on Equity for this stock declined to -101.12, with Return on Assets sitting at -54.11. When it comes to the capital structure of this company, Aerie Pharmaceuticals Inc. [AERI] has a Total Debt to Total Equity ratio set at 123.54. Additionally, AERI Total Debt to Total Capital is recorded at 55.27, with Total Debt to Total Assets ending up at 45.57. Long-Term Debt to Equity for the company is recorded at 120.25, with the Long-Term Debt to Total Capital now at 53.79.
Reflecting on the efficiency of the workforce at the company, Aerie Pharmaceuticals Inc. [AERI] managed to generate an average of -$525,213 per employee. Receivables Turnover for the company is 3.40 with a Total Asset Turnover recorded at a value of 0.19.Aerie Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 4.00 and a Current Ratio set at 4.30.
Aerie Pharmaceuticals Inc. [AERI]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, Aerie Pharmaceuticals Inc. posted -0.8/share EPS, while the average EPS was predicted by analysts to be reported at -0.86/share.When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 7.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for AERI.
An analysis of insider ownership at Aerie Pharmaceuticals Inc. [AERI]
There are presently around $846 million, in the hands of institutional investors. The top three institutional holders of AERI stocks are: WELLINGTON MANAGEMENT GROUP LLP with ownership of 6,736,222, which is approximately 7.934% of the company’s market cap and around 2.00% of the total institutional ownership; VANGUARD GROUP INC, holding 4,342,814 shares of the stock with an approximate value of $67.31 million in AERI stocks shares; and BLACKROCK INC., currently with $54.04 million in AERI stock with ownership of nearly 0.114% of the company’s market capitalization.
Positions in Aerie Pharmaceuticals Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 83 institutional holders increased their position in Aerie Pharmaceuticals Inc. [NASDAQ:AERI] by around 7,570,841 shares. Additionally, 87 investors decreased positions by around 11,645,563 shares, while 26 investors held positions by with 35,391,651 shares. The mentioned changes placed institutional holdings at 54,608,055 shares, according to the latest SEC report filing. AERI stock had 25 new institutional investments in for a total of 1,297,701 shares, while 38 institutional investors sold positions of 3,236,251 shares during the same period.